Aptose Biosciences (APTO) Stock Price, News & Analysis

Company Overview

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Key Stats

• Today's Range: $0.21 to $0.39
• 50-Day Range: $0.17 to $0.40
• 52-Week Range: $0.13 to $2.68
• Volume: 304.80 million shs
• Average Volume: 1.75 million shs
• Market Capitalization: $16.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.33
• Consensus Rating: Buy

Aptose Biosciences Stock Analysis - MarketRank™

Aptose Biosciences scored higher than 53% of companies evaluated by MarketBeat, and ranked 511th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Aptose Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Aptose Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Aptose Biosciences is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aptose Biosciences is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.21% of the float of Aptose Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Aptose Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aptose Biosciences has recently decreased by 15.66%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aptose Biosciences does not currently pay a dividend.

Dividend Growth

Aptose Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.21% of the float of Aptose Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Aptose Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aptose Biosciences has recently decreased by 15.66%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.09

News Sentiment

Aptose Biosciences has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Aptose Biosciences this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for APTO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Aptose Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Aptose Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $20,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 3.94% of the stock of Aptose Biosciences is held by insiders.

Percentage Held by Institutions

Only 26.62% of the stock of Aptose Biosciences is held by institutions.

APTO Stock Analysis - Frequently Asked Questions

How have APTO shares performed this year?

Aptose Biosciences' stock was trading at $2.54 at the beginning of 2024. Since then, APTO stock has decreased by 89.0% and is now trading at $0.2790.
View the best growth stocks for 2024 here.

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (NASDAQ:APTO) issued its earnings results on Thursday, August, 8th. The biotechnology company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.15.

When did Aptose Biosciences' stock split?

Shares of Aptose Biosciences reverse split before market open on Tuesday, June 6th 2023. The 1-15 reverse split was announced on Tuesday, June 6th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Aptose Biosciences' major shareholders?

Top institutional shareholders of Aptose Biosciences include Sigma Planning Corp (2.22%). Insiders that own company stock include William G Rice and Bernd R Seizinger.
View institutional ownership trends.

How do I buy shares of Aptose Biosciences?

Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aptose Biosciences investors own include Block (SQ), Digital Turbine (APPS), Okta (OKTA), Canoo (GOEV), CrowdStrike (CRWD) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:APTO
• CUSIP: N/A
• CIK: 882361
• Web: www.aptose.com
• Phone: 858-926-2730
• Fax: 905-234-2120
• Employees: 31
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.33
• High Stock Price Target: $6.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +1,453.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-51,210,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -5,683.22%
• Return on Assets: -300.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.05
• Quick Ratio: 1.05

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.19) per share
• Price / Book: -1.47

Miscellaneous

• Outstanding Shares: 60,181,000
• Free Float: 57,176,000
• Market Cap: $16.79 million
• Optionable: No Data
• Beta: 1.06